UBS Downgrades Chemours to Neutral, Lowers Price Target to $18

Chemours Co.

Chemours Co.

CC

0.00

UBS analyst Joshua Spector downgrades Chemours (NYSE: CC) from Buy to Neutral and lowers the price target from $29 to $18.